Jinatek

History

2025: Bronchodilator Production Launch

Irkutsk region One of the manufacturers of bronchodilators will appear in. The launch of the project for the development and production of bronchodilators on the basis of Jinatek LLC was initiated Russian pharmaceutical by the enterprise JSC "," Pharmasinthesis which announced this on September 11, 2025.

The release of the first batch of drugs for the treatment of chronic lung diseases, including chronic obstructive pulmonary disease (COPD) and asthma is planned in the near future.

According to Olga Danyushkina, General Director of Jinatek LLC, the first original drug, Dimplirin, has already been developed and registered, the subsequent ones are in the active stage of development and will enter the market in the near future. In total, the company plans to produce three dozen medicines by the end of the decade.

Our goal is to become one of the leading domestic manufacturers of high-quality, effective and affordable medicines for the treatment of diseases of the bronchopulmonary system, providing in the medium term a share in the Russian bronchodilator market of more than 25%, "the head of the company emphasized.

The manufacturer will establish a full production cycle, including the creation of finished dosage forms on the basis of the plant in Irkutsk. The number of jobs created is more than 100.

The products of Jinatek LLC are designed to significantly increase the availability of high-quality therapy to patients suffering from respiratory pathologies, ensure a significant reduction in the cost of states purchasing expensive foreign analogues and contribute to improving health. of the country's population Respiratory diseases remain one of the key medical problems of our time. By, to data WHO COPD is one of the six main reasons death in the world.

Russia faces a high incidence of COPD and severe asthma, which creates significant economic losses for the state, reaching hundreds of billions of rubles annually. Jinatek LLC intends to change the situation thanks to affordable domestic medicines of high quality, which are not inferior in effectiveness and safety to foreign drugs.

Now we are the only enterprise in Siberia producing drugs for the treatment of asthma and COPD. After the COVID-19 pandemic, the number of patients increased sharply, so we headed for this sector to support the population of our country. There is a lot of work ahead, and we are fully ready for it, - said Olga Danyushkina.